Traded Sep 28, 2026 · largest single transaction ~$20.2M
Show all 5 transactions
Sep 28, 2026~$20.2M · 279K sh @ $72.39
Loading…
KOD · NASDAQ · Biological Products, (No Diagnostic Substances)
Biological Products, (No Diagnostic Substances) company based in Palo Alto, Ca.
In the last 90 days, insiders of Kodiak Sciences reported 82 open-market purchases worth about $157M and 0 open-market sales. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 6, 2026
$92.34
Last 12 months
Not enough history
Market value
Not available
Bets against the stock: 10.7M shares sold short, −1.0% vs the previous count, 17.9 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Revenue
—
Free cash flow, last 12 months
−$160M
This quarter −$46.6M, a year earlier −$34.8M
Net debt
—
Debt —, cash $126M, at Jun 30, 2026
Net income, last 12 months
−$242M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 13, 2026.
Insiders buying, last 90 days
1 insider
$157M bought in total
Insiders selling, last 90 days
None
No open-market sales reported
New federal contracts, 12 months
None
Nothing found for this company
Traded Sep 28, 2026 · largest single transaction ~$20.2M
Sep 28, 2026~$20.2M · 279K sh @ $72.39
Sep 28, 2026~$17.7M · 197K sh @ $89.86
DetailsOfficial recordSep 28, 2026~$10.4M · 124K sh @ $83.95
DetailsOfficial recordSep 28, 2026~$9.55M · 108K sh @ $88.65
DetailsOfficial recordSep 28, 2026~$9.32M · 110K sh @ $84.85
DetailsOfficial recordPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
4 active phase 3 trials and 0 active phase 2 trials led by this company, mostly in macular edema secondary to inflammation, wet age-related macular degeneration, diabetic macular edema (dme). The ones with the nearest registered primary completion date still ahead:
1 trial has a registered primary completion date that has already passed. That usually means the data are being analysed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.